20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.
about
Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.Distribution of hepatitis B virus genotypes in blood donors and chronically infected patients in a tertiary care hospital in southern India.Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.Management of viral hepatitis B.Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.Hepatitis B viral genotypes: clinical relevance and molecular characteristics.Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.Hepatitis B virus resistance to lamivudine and its clinical implications.European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypesGenotyping the hepatitis B virus with a fragment of the HBV DNA polymerase gene in Shenyang, ChinaSimultaneous quantification and genotyping of hepatitis B virus for genotypes A to G by real-time PCR and two-step melting curve analysis.Serodiagnosis for tumor viruses.Early detection of hepatitis B drug resistance: implications for patient management.Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhoticsResponse to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.A novel hepatitis B virus genotyping system by using restriction fragment length polymorphism patterns of S gene amplicons.Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy.Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trialTherapeutic implications of hepatitis B virus genotypes.A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.Future prospectives for the management of chronic hepatitis B.Hepatitis B virus genotypes: natural history and implications for treatment.Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares.Molecular methods in the diagnosis and management of chronic hepatitis B.Prevalence of HBV genotypes among Egyptian hepatitis patients.Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors.Lamivudine monotherapy in chronic hepatitis B patients from the Indian subcontinent: antiviral resistance mutations and predictive factors of treatment response.Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment.Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant.Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan.Viral features of lamivudine resistant hepatitis B genotypes A and D.Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation.Hepatitis B virus genotypes in Europe.Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B.Sequence analysis of sub-genotype D hepatitis B surface antigens isolated from Jeddah, Saudi Arabia.Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.
P2860
Q31132087-52287526-29C7-414C-9D12-D4A72A004078Q33202621-ADE35A66-3BBA-4E4A-8DCD-E3022385470FQ33950133-93D198CE-77B2-4A37-A3B0-3656F9C78953Q33959006-F2849BF9-841E-4C26-8078-F894EE96F78EQ34700034-DF82A3CB-C809-42AE-877D-59FA28E1F735Q34723072-69660A20-0594-4725-B933-FAC32CBC6F4DQ34756218-60E9D5D9-2860-4788-BEB0-CEE7268F3786Q35007583-C9FA2308-900B-433A-9CDA-914EE54B7A13Q35073136-D0C3BF75-09F2-43CE-A4BE-301B60C8340DQ35093356-E94E2D51-E5BE-42F4-AE58-8619B4E94F52Q35220978-763C2B73-6B2E-4D11-9B3F-BC1D9606C5A1Q35289576-A34AC31A-D8DD-426E-BAA7-6E994BFD3DCDQ35543876-14A440DE-0AC7-4CEF-9CCA-FEF2B1C66F8EQ35615890-411235EB-79A7-4F0F-B28B-8A5C7D390091Q36177722-09333A01-7456-494E-B61E-BCBB5BB0DEE8Q36178096-DC49D2BF-A87D-4157-9B64-49A171AE2B12Q36234130-B5CBAF31-B79B-4C7C-B0E1-9C3F3EA3CAD9Q36308839-878084AD-1D30-4835-A41D-DD9C6022FF22Q36338675-F767063F-EFE4-4454-98A0-9B5F414B5438Q36445386-3DD08BD0-9D8E-422C-930A-974DD43B53E0Q36841719-41D5E136-D53E-4A3E-8CC6-CE468EAEE710Q37346012-7A69DD61-66CE-4C39-958B-67C18E13D562Q37511410-050382C6-4AF9-4A03-9DBE-9603CD617E76Q37801940-36D62DCB-889D-40EA-809A-5A2847CBAF13Q39131034-169A2876-91D6-4FAA-8E77-FF339A44FCD8Q40197893-44FDB5E9-17B7-4FB7-BDF3-24A8C4C1B147Q42270061-8BBCE56E-E4FE-4E97-A422-6B83907AED18Q43952840-D6FE937B-F518-4A7A-8008-F322478B0B77Q44355905-7329BA35-0337-4CF9-9EB8-1C0A88CA038AQ44461497-663E067D-FFDA-4496-9E97-ED5836479DA4Q44489295-5583EDB6-54E6-4A9D-AD17-8BEF0F7765E8Q44749272-5B1F2CA5-2910-4DD8-8EB7-4B9C07C3459FQ44963391-A2B88C46-BABA-4A63-9887-80FC1BA133CAQ45275480-C0ACB8A7-A77B-4168-85B3-189E58CDBF3BQ45438761-FB3C8F20-8163-452E-89A0-EDB47B35D97AQ54217666-61EB63A6-4E25-41C2-9BD4-89FA934200CBQ55223784-E8BC4EB7-C4FB-43B7-8269-8A3FDDA6E2E5
P2860
20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.
@en
20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.
@nl
type
label
20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.
@en
20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.
@nl
prefLabel
20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.
@en
20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.
@nl
P2093
P1433
P1476
20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.
@en
P2093
P304
P356
10.1016/S0140-6736(00)04219-7
P407
P577
2001-03-01T00:00:00Z